Literature DB >> 29600097

Concurrent thymic carcinoma and middle lobe syndrome.

Xi Zheng1, Yue Huang2, Junhe Gou3, Daxing Zhu1, Qinghua Zhou1.   

Abstract

Surgery is one of the first-line treatments for thymic carcinoma. Middle lobe syndrome which is irresponsive to conservative therapies also calls for surgical intervention. We reported the case of a 65-year-old male who was diagnosed with coexistent thymic carcinoma and non-obstructive middle lobe syndrome. Before the operation, we took measures including repeated sputum examination, physical therapy, postural sputum drainage and bronchodilator inhalation. After removal of the mediastinal neoplasm, venous antibiotics were used to prevent pneumonia. The preexistent cough with purulent expectoration still lasted, but no pulmonary infection occurred. Our report indicates that middle lobe syndrome may not increase respiratory complications after midline sternotomy if it receives proper treatments before the operation. For patients with concurrent thymic carcinoma and persistent middle lobe atelectasis, the thymic tumor might be treated with priority to increase the chance of complete resection.

Entities:  

Keywords:  Thymoma; comorbidity; middle lobe syndrome; pneumonia

Year:  2018        PMID: 29600097      PMCID: PMC5863109          DOI: 10.21037/jtd.2017.12.21

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  7 in total

1.  Risk factors for postoperative pneumonia after lung cancer surgery and impact of pneumonia on survival.

Authors:  Dennis F Simonsen; Mette Søgaard; Imre Bozi; Charles R Horsburgh; Reimar W Thomsen
Journal:  Respir Med       Date:  2015-07-17       Impact factor: 3.415

2.  Clinical practice guidelines for antimicrobial prophylaxis in surgery.

Authors:  Dale W Bratzler; E Patchen Dellinger; Keith M Olsen; Trish M Perl; Paul G Auwaerter; Maureen K Bolon; Douglas N Fish; Lena M Napolitano; Robert G Sawyer; Douglas Slain; James P Steinberg; Robert A Weinstein
Journal:  Am J Health Syst Pharm       Date:  2013-02-01       Impact factor: 2.637

3.  Ten years' experience in surgical treatment of right middle lobe syndrome.

Authors:  Saviz Pejhan; Farshid Salehi; Shanay Niusha; Behrooz Farzanegan; Kambiz Sheikhy
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-03-02       Impact factor: 1.520

Review 4.  Myasthenia gravis: subgroup classification and therapeutic strategies.

Authors:  Nils Erik Gilhus; Jan J Verschuuren
Journal:  Lancet Neurol       Date:  2015-10       Impact factor: 44.182

5.  Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective analysis of 105 cases.

Authors:  Yang Zhao; Heng Zhao; Dingzhong Hu; Limin Fan; Jianxin Shi; Wentao Fang
Journal:  Ann Thorac Surg       Date:  2013-07-16       Impact factor: 4.330

Review 6.  State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma.

Authors:  Michael Ried; Alexander Marx; Andrea Götz; Okka Hamer; Berthold Schalke; Hans-Stefan Hofmann
Journal:  Eur J Cardiothorac Surg       Date:  2015-12-15       Impact factor: 4.191

Review 7.  Surgical Approaches for Stage IVA Thymic Epithelial Tumors.

Authors:  Mark Shapiro; Robert J Korst
Journal:  Front Oncol       Date:  2014-01-14       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.